GLP-1 receptor agonists demonstrate dose-dependent weight loss ranging from 8.8% with liraglutide to 21.5% with dual GIP/GLP-1 therapies, while delivering measurable cardiometabolic improvements including HbA1c reductions up to 1.78% and systolic blood pressure drops of 5-8 mmHg. Tirzepatide emerged as particularly effective at 15-18.5% weight loss, while semaglutide 2.4mg achieved 14.9-15.2% reductions. This systematic analysis of 15 studies reinforces what clinicians have observed: these medications represent a paradigm shift in obesity treatment, moving beyond simple weight loss to address the metabolic syndrome constellation. The cardiometabolic benefits—improved glycemic control, blood pressure, and lipid profiles—suggest these drugs tackle obesity's root pathophysiology rather than just symptoms. Gastrointestinal side effects remain common but manageable, with discontinuation rates under 15%. For longevity-focused adults, these findings are significant because they demonstrate pharmaceutical intervention can simultaneously address multiple aging accelerators: excess weight, insulin resistance, hypertension, and dyslipidemia. However, this remains a medical intervention requiring professional oversight, and the long-term metabolic effects beyond the study periods require continued monitoring as these medications become more widely adopted.